Cardio Diagnostics Wins $854 CMS Reimbursement, Expands Provider Partnerships and India Launch
Cardio Diagnostics secured CMS reimbursement rate of $854 for its non-invasive AI-based cardiovascular tests and expanded provider partnerships nationwide. The company also launched its epigenetic-genetic diagnostic platform in India and presented clinical data showing detection of coronary heart disease forms missed by traditional methods.
1. Innovative Diagnostic Platform
Cardio Diagnostics leverages a proprietary platform integrating epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood draw. Its non-invasive tests require no fasting or radiation and target both inherited predisposition and lifestyle-influenced risk factors.
2. CMS Reimbursement and Commercial Channels
The company finalized a $854 reimbursement rate with CMS for its clinical tests and has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs to drive adoption across the United States.
3. International Expansion and Clinical Data
Cardio Diagnostics initiated its first international rollout in India and presented clinical findings demonstrating its ability to detect coronary heart disease types that traditional diagnostic tools often miss, supporting its precision medicine approach.